Kasia Rothenberg, PhD
Geriatric Psychiatry · Cleveland, OHNPI 1336466986
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 45.9% of the total. Reporting peaked in 2024 at $1,730 and has fallen 60.3% since, to $686 in 2025.
Across 47 payments — averaging $123.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Lundbeck LLC$1K
- Neurocrine Biosciences, Inc.$709
- Acadia Pharmaceuticals Inc$365
- Lilly USA, LLC$297
- Eisai Inc.$243
- plus $508 from 5 others
Across 2 payments — averaging $1776.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$4K
What the payments were for
- Consulting fees$1,32023%
- Speaking & faculty fees$88015%
- Travel & lodging$2334%
- Food & beverage$3,25856%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 18 | $2,661 |
| Lundbeck LLC | 2 | $1,018 |
| Neurocrine Biosciences, Inc. | 8 | $709 |
| Acadia Pharmaceuticals Inc | 5 | $365 |
| Lilly USA, LLC | 5 | $297 |
| Eisai Inc. | 3 | $243 |
| E.r. Squibb & Sons, L.L.C. | 1 | $233 |
| Tempus AI, Inc | 2 | $135 |
| Genentech USA, Inc. | 1 | $91 |
| Axsome Therapeutics, Inc. | 1 | $40 |
| Penumbra, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$1,907
- REXULTI$880
- INGREZZA$579
- Austedo XR$354
- KISUNLA$250
- Leqembi$222
- ABILIFY ASIMTUFII$138
- NUPLAZID$106
How this compares
Too few geriatric psychiatry providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 32 | $176,023 |
| AustedoDeutetrabenazine | 22 | $115,358 |
| Rivastigmine | 48 | $7,922 |
| Memantine Hcl | 189 | $5,642 |
| Donepezil Hcl | 235 | $2,593 |
| Aripiprazole | 17 | $2,050 |
| Sertraline Hcl | 146 | $1,961 |
| Mirtazapine | 40 | $1,095 |
| Quetiapine Fumarate | 75 | $1,020 |
| Duloxetine Hcl | 30 | $792 |
| Gabapentin | 49 | $708 |
| Escitalopram Oxalate | 53 | $629 |
| Olanzapine | 25 | $537 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $521 |
| Divalproex Sodium | 12 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $365 | $176,02332 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $2,661 | $115,35822 claims |
| Lilly USA, LLCOlanzapine | $297 | $53725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric psychiatry providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other geriatric psychiatry in Cleveland
- Brian ApplebyCleveland$6K
- Philipp DinesCleveland$462
- Babu GuptaCincinnati$11K
- Alfredo RiveraCincinnati$2K
- Chander MohanShelby$2K
- Rebecca SchlachetEuclid$496
- Louis KleinRocky River$280
- Upma DhingraEuclid$277
- Robert SegravesBeachwood$251
- Ravinder MannCincinnati$202
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.